Metis TechBio

Metis TechBio (Ticker: 7666 HK) develops drug formulations for therapeutic delivery, using platforms with applications in human therapeutics, longevity and animal health. Its platforms include NanoForge, AiTEM, AiLNP and AiRNA. Its most advanced drug candidate, MTS-004, has completed Phase III clinical trial development. The offering includes a 15% greenshoe option. Proceeds are intended for research and development, product capacity, brand promotion and business development, working capital, strategic acquisitions and other purposes.

The scheduled listing date on Hong Kong Stock Exchange was May 13, 2026. The proposed offering comprises 201,230,000 shares at an indicative price of HKD 10.50 per share. The base offering would represent HKD 2.11 billion, approximately $269.23 million in gross proceeds, excluding any unexercised over-allotment. The indicated IPO market capitalization is $1.40 billion.

The IPO managers are CLSA, CMB International, Deutsche Bank, Futu Securities and Jefferies.